ReviewCell stem cell2011
Inducing iPSCs to escape the dish.
Review in Cell stem cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Biological function and application of melanocytes induced and transformed by mouse bone marrow mesenchymal stem cells.Regenerative therapy · 2022Article
- Stem cell-based therapy for pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Selection of different endothelialization modes and different seed cells for tissue-engineered vascular graft.Bioactive materials · 2021Review
- Bioengineering human vascular networks: trends and directions in endothelial and perivascular cell sources.Cellular and molecular life sciences : CMLS · 2019Review
- ERBB3-Binding Protein 1 (EBP1) Is a Novel Developmental Pluripotency-Associated-4 (DPPA4) Cofactor in Human Pluripotent Cells.Stem cells (Dayton, Ohio) · 2018Article
- Behavior of Xeno-Transplanted Undifferentiated Human Induced Pluripotent Stem Cells Is Impacted by Microenvironment Without Evidence of Tumors.Stem cells and development · 2017Article
- Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta.Journal of visualized experiments : JoVE · 2017Article
- Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis.Stem cell reviews and reports · 2015Review
- Continuous non-cell autonomous reprogramming to generate retinal ganglion cells for glaucomatous neuropathy.Stem cells (Dayton, Ohio) · 2015Article
- Databases and collaboration require standards for human stem cell research.Drug discovery today · 2015Review
- Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, and In Vitro Disease Modeling.Stem cells international · 2015Review
- Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement.Acta biomaterialia · 2014Article
- Understanding the roadmaps to induced pluripotency.Cell death & disease · 2014Review
- Reprogramming to a pluripotent state modifies mesenchymal stem cell resistance to oxidative stress.Journal of cellular and molecular medicine · 2014Article
- Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.International journal of molecular sciences · 2014Review
- The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.The Journal of biological chemistry · 2014Review
- Grand challenges in the field of stem cell research.Frontiers in cell and developmental biology · 2014Article
- A small-molecule inducer of PDX1 expression identified by high-throughput screening.Chemistry & biology · 2013Article
- Cardiac stem cells and their roles in myocardial infarction.Stem cell reviews and reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Induced pluripotent stem cells (iPSCs) hold great promise for autologous cell therapies, but significant roadblocks remain to translating iPSCs to the bedside. For example, concerns about the presumed autologous transplantation potential of iPSCs have been raised by a recent paper demonstrating that iPSC-derived teratomas were rejected by syngeneic hosts. Additionally, the reprogramming process can alter genomic and epigenomic states, so a key goal at this point is to determine the clinical relevance of these changes and minimize those that prove to be deleterious. Finally, thus far few studies have examined the efficacy and tumorigenicity of iPSCs in clinically relevant transplantation scenarios, an essential requirement for the FDA. We discuss potential solutions to these hurdles to provide a roadmap for iPSCs to "jump the dish" and become useful therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.